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Patient stratification in clinical 
glaucoma trials using the individual 
tear proteome
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Roger W. Beuerman1,2,3 & Hannu Uusitalo1,4
Glaucoma patients are prone to concomitant ocular surface diseases; however, switching from 
preserved to preservative-free medication can often alleviate these symptoms. The objective of this 
study was to examine how the adverse effects and tear proteome change for glaucoma patients 
(n = 28) during a 12-month drug switch from preserved latanoprost (Xalatan) to preservative-free 
tafluprost (Taflotan). We hypothesized that patient stratification could help identify novel recovery 
patterns in both tear proteomics and clinical data. In order to accomplish patient stratification, we 
implemented sequential window acquisition of all theoretical mass spectrometry (SWATH-MS) as a 
tool for quantitative analysis of individual tear protein profiles. During each visit (baseline and four 
follow-up visits), the patients’ tears were sampled and the state of their ocular surface was evaluated 
clinically. Altogether 785 proteins were quantified from each tear sample using SWATH strategy and 
as these protein expression levels were compared between baseline and 12-month follow-up, three 
distinct patient groups were identified. We evaluated how these patient groups differed in their protein 
expression levels at baseline and discovered that the patients with increased levels of pro-inflammatory 
proteins and decreased levels of protective proteins benefitted most from the medication switch.
Glaucoma is a collection of diseases, which can all ultimately result in degeneration of the optic nerve and blind-
ness1. In order to halt the glaucomatous changes in the eye, glaucoma treatments attempt to lower the elevated 
intraocular pressure (IOP), one of the most frequent characteristics of glaucoma, via topical and oral drugs, 
laser procedures or surgery. Topical treatment is currently the most common glaucoma management method. 
However, a number of previous studies have shown that prolonged use of topical glaucoma medication may 
induce symptoms and signs of ocular surface disease, chronic inflammation and other anterior segment dis-
eases2–4. The exact cause of the adverse effects are debated, but they could be caused by the active compounds 
in the eye drops or by the solution preservative such as benzalkonium chloride (BAK) – the most well-known 
and commonly used preservative in topical glaucoma medication3,5,6. Clinical evidence suggests that patients 
suffering from adverse reactions whilst using preserved topical treatments generally benefit from a switch to 
preservative-free eye drops: their adverse reactions diminish without compromising the control of IOP7–12.
Tear proteome has shown its potential in identifying biomarkers for inflammatory responses associated with 
glaucoma medication; Wong et al.13 studied the differences in tear proteomics between glaucoma and control 
patients and Funke et al.14 examined the common proteomic changes after medication switch during a 6-month 
follow-up study with pooled patient samples. Proteomic biomarkers have also been successfully utilized to mon-
itor other eye diseases including dry eye, diabetic retinopathy and age-related macular degeneration15–22. To 
achieve the necessary precision, stratified patients within subgroups must have individual analysis. This is now 
feasible with label-free mass spectrometry methods, such as sequential window acquisition of all theoretical mass 
spectra (SWATH-MS), which enable studies of proteomic profiles of each individual patient even in large clinical 
trials15,23. Benefits of label-free MS include analysis of complex comparisons between clinical findings and the 
individual tear proteome24. This approach could become more widely used, if successful bioinformatic methods 
are developed. For example, we were able to examine why patients react in different ways to the same therapy and 
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study the underlying biological explanation. Focusing on patient stratification is the next natural step in medical 
research and is expected to become more popular in the future as the need for precision medicine rises25,26.
The aim of this study was to evaluate tear protein profiles of individual patients with ongoing glaucoma ther-
apy including BAK-preserved prostaglandin analogue, and proteomic changes after switching to preservative-free 
medication for a 12-month follow-up period. Our hypotheses were that the patients affected by the switch would 
also have noticeable changes in their tear protein profiles and that patient stratification could help identify novel 
recovery patterns in both proteomics and clinical data. Tear proteomics studies on glaucoma have been published 
previously13,14; however, our study is the first to our knowledge to use a precision medicine approach as well as 
SWATH and to stratify the glaucoma patients into groups based on their individual proteomic responses to med-
ication switch.
Results
Study population characteristics and clinical results. The study population consisted of 28 patients (7 
men and 21 women). Twenty-five patients were diagnosed with primary open-angle glaucoma and 3 with capsu-
lar glaucoma. The mean age of the patients in the beginning of the study was 67.4 years (95% CI: 64.5–70.3). The 
patients had been on preserved latanoprost treatment for 7.7 years on average (95% CI: 6.1–9.2).
Majority of the clinical signs and symptoms steadily improved throughout the 12 months after switch (Tables 1 
and 2). More specifically, the conjunctival redness and lid redness decreased while (fluorescein tear break-up time 
in seconds) FTBUT and Schirmer’s test values increased. Although the corneal and conjunctival staining scores 
did not change considerably, the overall means suggest that the scores decreased. In addition, all symptoms expe-
rienced by the patients improved after the switch, although some of these improvements were not statistically 
significant.
Relative protein expression levels can be used to stratify patients. We identified a total of 25,487 
peptides from 270 samples/MS analysis replicates, corresponding to 388,273 identified spectra in an assembly of 
1439 protein groups using FDR of 1.0%. Total of 950 proteins with distinctive peptides were included to quan-
tification library and from this library, 785 proteins had distinct peptide sequences with matching spectra to 
SWATH analysis and were quantified in all samples. The proteomic data exhibited good quality and reliability 
with p-value < 0.05 in 89% of replicate MS analyses (permutation tests, Spearman’s rank correlation) and mean 
intraclass correlation coefficient of 0.97.
We wanted to establish how each patient’s protein profile changed during the 12-month treatment period. 
To achieve this, we first clustered the log2 fold changes between the first and final visit, and based on the den-
drogram and visual inspection of results we set the cut-off at 7 clusters (Fig. 1). We then conducted pathway 
analysis with Ingenuity Pathway Analysis (IPA) for all 7 protein clusters and identified three clusters of interest, 
enriched with inflammatory proteins as shown in Supplementary Table S1. Within these clusters, protein profiles 
among patients became clearer during the 12-month follow-up (Fig. 1). The first protein cluster included several 
Clinical sign Baseline values
Change from baseline
1.5 months 3 months 6 months 12 months
Conjunctival redness
Mean 1.750 −0.286 −0.607 −0.75 −0.964
95% CI [1.459, 2.041] [−0.541, −0.03] [−0.873, −0.341] [−1.022, −0.478] [−1.188, −0.741]
Pa 0.04* <0.001*** <0.001*** <0.001***
Lid redness
Mean 0.857 −0.357 −0.214 −0.464 −0.519
95% CI [0.605, 1.109] [−0.574, −0.14] [−0.48, 0.052] [−0.733, −0.196] [−0.836, −0.201]
Pa 0.004** 0.12 0.003** 0.005**
Fluorescein tear 
break-up time
Mean 5.393 1.786 2.179 3.214 4.444
95% CI [4.284, 6.501] [0.453, 3.118] [0.735, 3.622] [1.531, 4.897] [2.184, 6.705]
Pb 0.01* 0.005** <0.001*** <0.001***
Corneal staining
Mean 0.607 −0.429 −0.357 −0.286 −0.393
95% CI [0.252, 0.963] [−0.785, −0.072] [−0.741, 0.026] [−0.732, 0.16] [−0.792, 0.007]
Pa 0.02* 0.08 0.25 0.06
Conjunctival staining 
(nasal)
Mean 1.393 −0.25 −0.286 −0.393 −0.179
95% CI [1.070, 1.715] [−0.654, 0.154] [−0.633, 0.062] [−0.806, 0.02] [−0.614, 0.257]
Pa 0.31 0.12 0.07 0.53
Conjunctival staining 
(temporal)
Mean 1.571 −0.321 −0.393 −0.464 −0.357
95% CI [1.265, 1.878] [−0.656, 0.013] [−0.819, 0.034] [−0.852, −0.077] [−0.755, 0.041]
Pa 0.07 0.07 0.02* 0.08
Schirmer’s test
Mean 12.000 4.214 4.964 4.786 5.429
95% CI [8.511, 15.489] [1.987, 6.441] [1.349, 8.579] [1.288, 8.283] [2.622, 8.236]
Pb <0.001*** 0.009** 0.009** <0.001***
Table 1. Changes in clinical signs between baseline and the visits after medication switch. CI, confidence 
interval. *P < 0.05; **P < 0.01; ***P < 0.001; a2-group Wilcoxon Signed Rank Test; bPaired t-test.
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protective ocular surface biomarkers, such as lysozyme (LYZ), proline-rich protein 1 (PROL1) and various cys-
tatins. Altogether 71 proteins were in this cluster and the top enriched disease and function terms, according 
to IPA, included “activation of neutrophils” and “chronic inflammatory disorder”. The second cluster included 
inflammatory biomarkers such as albumin (ALB), serotransferrin (TF), protein S100A8 and annexins, with a total 
of 116 proteins all displaying similar fold changes. The top enriched terms for this cluster included “inflammation 
of organ” and “cell death”. The third cluster also included known inflammation biomarkers such as complement 
C3 (C3), alpha-enolase (ENO1) and protein S100A9. The 135 similarly expressed proteins in this cluster had 
enrichments relating to cell death, cell movement and inflammation of organ.
Next, it was possible to stratify patients into three groups, based on the changes in filtered proteomic profiles 
(Fig. 1). The patients in groups 1 and 2 showed somewhat similar improvement based on their proteomic pro-
file: expression of protective proteins increased and pro-inflammatory protein expression decreased. Heat map 
and clustering analysis further differentiated these groups; protein expression changes were more consistent for 
group 1 patients, while there was some variation among patients in group 2. The patients in group 3 experienced 
a decrease in protective proteins’ expression and an increase in expression of pro-inflammatory proteins, suggest-
ing that they were not benefitting from the drug switch.
Baseline expression levels of several proteins indicate individual differences between the 
patient groups. Next, we examined if baseline expression levels of individual proteins would differ between 
the three patient groups. After p-value adjustment, out of 322 clustered proteins, 31 remained statistically signifi-
cant (p-value < 0.05). We excluded one protein without a gene symbol (immunoglobulin), two proteins with une-
qual variance (heteroscedasticity, Levene’s test p-value < 0.05) and six proteins with poor peak matches, yielding a 
total of 22 proteins which differed between the patient groups at the baseline (Fig. 2). Many of the statistically sig-
nificant proteins were ordered in a similar manner; proteins in Fig. 2a had the highest expression among patients 
in group 1, then 2 and patients in group 3 had the lowest relative expression levels. This order was reversed for 
proteins in Fig. 2b, where group 1 patients had the lowest relative expression. The results also included some 
less consistent results, which could none-the-less provide further, interesting information of the patient groups 
(Fig. 2c). More detailed statistics results are provided in Supplementary Table S2.
Protein expression levels correlate with Schirmer’s test and FTBUT values. Next, we wanted 
to compare clinical results with tear proteomics data and performed mixed effects model analysis. All 
pro-inflammatory proteins that differed between the patient groups at baseline (Fig. 2a), excluding pro-apoptotic 
cytosolic non-specific dipeptidase (CNDP2), correlated negatively with Schirmer’s test results (Fig. 3a), and four 
correlated negatively with FTBUT (Fig. 3b). The cystatins, PROL1 and beta-2-microglobulin (B2M) (Fig. 2b) 
correlated positively (Fig. 3a) and acyl-CoA-binding protein (DBI) (Fig. 2c) correlated negatively with Schirmer’s 
test. Full statistical results are available in Supplementary Table S3. To conclude, we observed that Schirmer’s 
test and FTBUT values correlate negatively with pro-inflammatory proteins and the correlation is positive with 
protective proteins.
Patient groups and their differences in clinical signs and symptoms. Finally, we analysed how the 
clinical signs and symptoms changed within the identified patient groups. Since patient group 1 had only four 
patients, we decided to combine groups 1 and 2 and this way, patients groups 1 and 2 together show patients, 
who appear to benefit from the drug switch and group 3 includes patients who do not. The results for the clinical 
sign changes showed that while there was beneficial development for both groups 1 and 2 together and group 3, 
the changes for patient group 3 were not often statistically significant (Fig. 4). For example, Schirmer’s test and 
Clinical symptom Baseline values
Change from baseline
1.5 months 3 months 6 months 12 months
Irritation, 
burning, 
stinging
Mean 1.143 −0.071 −0.179 −0.143 −0.143
95% CI [0.629, 1.657] [−0.738, 0.595] [−0.855, 0.498] [−0.849, 0.563] [−0.737, 0.451]
Pa 0.73 0.65 0.61 0.66
Itching
Mean 1.821 −0.643 −0.821 −0.643 −0.75
95% CI [1.361, 2.282] [−1.14, −0.145] [−1.339, −0.304] [−1.162, −0.124] [−1.284, −0.216]
Pa 0.02* 0.007** 0.02* 0.01*
Foreign 
body 
sensation
Mean 1.571 −0.786 −1 −0.964 −0.393
95% CI [1.061, 2.082] [−1.328,−0.244] [−1.615, −0.385] [−1.497, −0.432] [−1.055, 0.269]
Pa 0.008** 0.009** 0.003** 0.30
Tearing
Mean 1.893 −0.929 −1.036 −1.393 −1
95% CI [1.321, 2.464] [−1.466, −0.391] [−1.673, −0.398] [−1.934, −0.851] [−1.517, −0.483]
Pa 0.004** 0.009** <0.001*** 0.002**
Dry eye 
sensation
Mean 2.071 −0.357 −0.536 −0.679 −0.607
95% CI [1.555, 2.588] [−0.855, 0.14] [−0.951, −0.12] [−1.247, −0.11] [−1.294, 0.08]
Pa 0.16 0.03* 0.03* 0.09
Table 2. Changes in clinical symptoms between baseline and the visits after medication switch. CI, confidence 
interval. *P < 0.05; **P < 0.01; ***P < 0.001; a2-group Wilcoxon Signed Rank Test.
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FTBUT increased significantly for groups 1 and 2 together but not for group 3. Similarly, conjunctival redness 
and lid redness decreased throughout the study for groups 1 and 2, but the changes for group 3 were not consist-
ently significant. Same analysis was also performed for the clinical symptoms (Fig. 5). Groups 1 and 2 had more 
significant decreases in itching and foreign body sensation while irritation/burning/stinging, tearing and dry eye 
sensation changes were not as consistent with previous findings.
Discussion
In our study, as with previously published studies, patients experiencing adverse effects from long-term use of 
BAK-preserved topical glaucoma medication benefitted from a switch to a preservative-free topical treatment 
according to majority of the clinical signs. However, based on our previous clinical data7,8 and the present pro-
teomic data stratification, the level of this improvement varied among patients. In order to examine differences 
between patients on proteome level, we stratified patients based on expression changes between baseline and 
final visit (V1-V5) and identified differences in proteins connected to inflammation. Our results showed that the 
patients had different patterns of protein expression, which became more consistent and clear with time, forming 
three patient groups towards the end of the study: greatly improved (group 1), moderately improved (group 2) 
and unimproved (group 3) proteomic profiles.
When comparing baseline protein expression levels of the three patient groups, we identified 22 proteins 
that were differentially expressed. The most improved patients (group 1) had higher baseline expression lev-
els of several known pro-inflammatory proteins, which were in relation low in expression for the unimproved 
patients (group 3). These proteins included the 14-3-3 protein epsilon (YWHAE) and 14-3-3 protein zeta/delta 
(YWHAZ), which belong to the same protein family and YWHAZ has been previously found to be upregulated 
Figure 1. Outline and results from the patient stratification. The top row explains the outline of data processing, 
protein clustering and patient stratification. The heat maps visualize the change in protein expression between 
baseline and time points after the medication switch. V refers to visits and focus is on the V1-V5 comparison. 
Two protein clusters associated with pro-inflammation are indicated in grey rows, and proteins linked to 
ocular surface protection in white rows. The differences between the patient groups become clearer with time, 
as is visualized by the additional heat maps (V1-V2, V1-V3 and V1-V4) showing expression differences in 
comparison to baseline. Two patients were excluded due to missing baseline expression and in addition, two 
patients had no V4 data. ALB, albumin; C3, complement C3; ENO1, alpha-enolase; LPO, lactoperoxidase; LYZ, 
lysozyme; PROL1, proline-rich protein 1; TF, serotransferrin.
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in the tears of patients using topical anti-glaucoma medication13. Similarly heat shock proteins (HSP) HSPA5 
and HSPA8, had increased expression levels among most improved patients in our results. These proteins tend 
to be highly expressed in glaucomatous eyes27 and are associated to environmental stress; however, their con-
nections to glaucoma medication have not been examined. Other similarly expressed proteins connected to 
ocular inflammation were iron transport protein transferrin (TF)28, which has been found to be upregulated in 
glaucoma and in particular with patients using preserved medication14,29, and protein S100A6, which is upreg-
ulated in dry eye disease30. In addition, myosin light polypeptide 6 (MYL6) had expression level similar to the 
other pro-inflammatory proteins and interestingly, the myosin light chains (MLC) have previously been linked to 
BAK-related inflammation31,32.
The proteins with low expression among the most improved patients (group 1) and higher expression for 
the unimproved patients (group 3) included several cystatins (cystatins S (CST4), SA (CST2) and SN (CST1)), 
lacrimal gland secreted PROL1 and B2M. Of these proteins CST4, CST1, B2M and PROL1 have been found to 
be decreased in dry eye disease20,33–35. Based on these “beneficial” proteins, as well as the pro-inflammatory pro-
teins previously described, the patients who experience the greatest improvement are patients with the highest 
initial expression levels of pro-inflammatory proteins and lowest expression of protective proteins. This suggests 
Figure 2. Proteins (y-axis) with differing baseline log2 expressions (x-axis) between the patient groups. Protein 
expression of several pro-inflammatory proteins is highest at baseline for patients in group 1, intermediate 
in group 2, and lowest in group 3 (a). Protein expression levels of various cystatins, proline-rich protein 1 
(PROL1), and beta-2-microglobulin (B2M), considered to be beneficial, are lowest for group 1 patients, 
intermediate in group 2, and highest in group 3 (b). A collection of proteins not following the same order as 
in A and B (c). Measures are shown as mean ± s.e.m. and all proteins missing a specification (*, a or b) have 
a statistical difference between patient groups 1 and 2, and 1 and 3 (Welch’s analysis of variance). *Significant 
differences between all patient groups; aPatient group 3 differs significantly from other groups; bPatient groups 1 
and 2 differ from each other significantly.
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that patients with more severe ocular surface condition benefit from the switch the most and that the differences 
among patients can be discovered using proteomics.
Next, we wanted to combine all the clinical and proteomic information in the light of our results. More specif-
ically, we wanted to see if there were any statistically significant correlations between the proteins of interest and 
the clinical signs. We observed that low Schirmer’s test and FTBUT values were associated with high expression 
of pro-inflammatory proteins and low expression of cystatins, PROL1 and B2M. These statistically significant 
correlations between the protein expression levels and clinical signs further confirmed the roles of the proteins, 
which we have previously described.
Finally, we compared the patient groups’ clinical sign and symptom development after the switch and noted 
that the signs and symptoms were significantly improving for many patients in groups 1 and 2, i.e. those who 
were benefitting from the drug switch based on proteomics data. Patients in group 3 were also moderately 
improving, but for the majority of signs and symptoms, this was not statistically significant. This suggests that the 
pro-inflammatory and protective proteins do identify patients benefitting from the switch also based on clinical 
parameters, such as Schirmer’s test, FTBUT, corneal staining, lid redness, tearing and foreign body sensation.
Our results suggesting there is a subgroup of patients not benefitting from the switch was not surprising, since 
the growing consensus is that individual response to medications can widely vary and has been also indicated by 
Figure 3. Schirmer’s test and fluorescein tear break-up time (FTBUT) correlate with statistically significant 
proteins identified in the study. Serotransferrin (TF), S100A6 and 14-3-3 protein zeta/delta (YWHAZ) 
expression levels correlate negatively with Shirmer’s test, while proline-rich protein 1 (PROL1), cystatin 
S (CST4) and beta-2-microglobulin (B2M) have a positive correlation (a). TF, heat shock cognate 71 kDa 
protein (HSPA8) and YWHAZ expression levels correlate negatively with FTBUT (b). Statistically significant 
correlations were identified using mixed model regression and the data are shown as boxplots displaying 
median, 25 and 75 quartiles, 5 and 95 percentiles (error bars). Black dots represent potential outliers.
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previous clinical studies8. However, with other studies, the sample sizes have been relatively large and it is pos-
sible that smaller subgroups get overrepresented in smaller studies such as ours. One hypothesis to explain the 
varying changes after switch is that these patients could be more sensitive to active compound of the drug, such 
as prostaglandin analogue, which is also known to cause adverse reactions on ocular surface36,37. Alternatively, 
these unimproved patients could be suffering from other ocular surface conditions, which are unrelated to the 
BAK-effects. Either way, this topic deserves further examination.
In our current study, the analysis of the protein expression levels was done with respect to the follow-up data 
of other patients suffering from adverse effects and by analysing the changes after the omission of preservatives. 
A control population could have helped us make concrete conclusions about up- or downregulation of proteins. 
Figure 4. Changes in clinical signs between baseline and the visits after medication switch for groups 1 and 2 
(improved patients), and group 3 (unimproved patients). As seen from the visits (x-axis), as time progresses, 
the mean (±se) change (y-axis) of conjunctival redness (a) and lid redness (b) decreased for groups 1 and 2 as 
well as for group 3, yet the changes were only statistically significant for the former. Similarly, fluorescein tear 
break-up time (FTBUT) (c) and Schirmer’s test (g) were increased for all patients, however only group 1 and 2 
patients had statistically significant improvement. Corneal (d) and conjunctival staining (e,f) were not showing 
similar signs of improvement, which matches previous results. Measures are shown as mean ± s.e.m change 
from baseline and continuous signs (c,d) were analysed with paired t-test and the rest with paired 2-group 
Wilcoxon signed rank test. *P < 0.05; **P < 0.01; ***P < 0.001.
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However, we have already begun work to identify the normal expression levels of these proteins in population of 
normal subjects of various ages.
In conclusion, by implementing SWATH method for quantitative analysis of individual tear protein profiles, 
we discovered that patients react differently when switched to preservative-free glaucoma medication and their 
condition continues to change for at least 12 months. This study demonstrates that when analysing the pro-
teomic profiles, the patients should be analysed separately as they experience different changes in expression 
of inflammation-related proteins. In addition, knowledge of the baseline protein expression is crucial in stud-
ies focusing on patient stratification. Hence, in order to obtain versatile data needed for patient stratification, 
mass spectrometry method should be chosen carefully. The overall results of this study suggest that the patients 
who have the most severe BAK-induced adverse effects benefit most from the switch and that these patients 
could be detected using tear proteomics. This further suggests that a subgroup of the patients are suffering from 
some other, BAK-independent, ocular surface-related conditions, and should be treated accordingly to improve 
the well-being of these patients. We identified several potential biomarkers, such as pro-inflammatory proteins 
YWHAE and YWHAZ and various beneficial cystatins, which may indicate whether the patient will benefit from 
a switch to other therapeutic treatments. Proteomic tear fluid biomarkers provide efficient tools for developing 
precision therapeutic strategies for glaucoma patients and deserve further studies.
Methods
Study population. The study was conducted in accordance with the International Conference of 
Harmonization Good Clinical Practice guidelines and the Declaration of Helsinki. Study was approved by the 
Ethics Committee at Tampere University Hospital and was registered in EU Clinical Trials Register (EudraCT 
Number: 2010-021039-14, registration date: 3/28/2010, online: https://www.clinicaltrialsregister.eu/ctr-search/
search?query=eudract_number:2010-021039-14). Each patient signed a written informed consent before inclu-
sion in the study.
The patients were assessed during the baseline visit and eligible patients had primary open angle or capsu-
lar glaucoma. The included patients had also been receiving preserved latanoprost treatment for 6 months or 
Figure 5. Changes in clinical symptoms between baseline and the visits after medication switch for groups 
1 and 2 (improved patients), and group 3 (unimproved patients). Irritation/burning/stinging (a) was not 
changing significantly in any time point (x-axis), while itching (b) and foreign body sensation (c) were 
significantly reduced for groups 1 and 2. Some evidence of reduction was also present for tearing (d) and dry 
eye sensation (e). Measures are shown as mean ± s.e.m change from baseline and were analysed with paired 
2-group Wilcoxon signed rank test. *P < 0.05; **P < 0.01; ***P < 0.001.
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longer for both eyes and exhibited at least two ocular symptoms or one symptom and one sign of ocular surface 
irritation/inflammation. Thirty patients were selected for this study based on these inclusion criteria. One of the 
patients died during the follow-up and one discontinued the study and hence, the final study population was 
reduced to 28 patients. Although both eyes were examined for each patient, only the right eyes were included in 
the analysis.
Patients who were excluded from the study had pigmentary or angle-closure glaucoma, IOP higher than 
22 mmHg in baseline, corneal abnormalities affecting tonometry, had undergone a recent (within 6 months) 
ocular surgery including laser procedures, wore contact lenses, or were using artificial tears containing preserv-
atives. In addition, pregnant and nursing women as well as women of childbearing potential without adequate 
contraception were excluded.
Study outline. The study consisted of 6 visits: screening/baseline visit, visits at 1.5, 3, 6 and 12 months after 
the baseline, and 1–4 weeks after the 12-month visit (Fig. 6). At baseline visit, the patients were switched from pre-
served latanoprost (Xalatan, Pfizer Inc., New York, NY, USA) to preservative-free tafluprost (Taflotan, Santen Inc., 
Osaka, Japan) and their clinical signs and symptoms, and medical history were recorded. The preservative-free 
eye drops were administered once a day for the duration of the study. The tear fluid samples for proteomics anal-
ysis were collected using a Schirmer’s strip and in addition, ocular examinations and procedures were performed 
during each visit including ocular symptoms (irritation/burning/stinging, itching, foreign body sensation, tear-
ing, dry eye sensation), conjunctival hyperaemia, fluorescein staining of cornea and nasal and temporal conjunc-
tiva, FTBUT, lid redness, and Schirmer’s test. The ocular symptoms were graded between 0 and 4 in the following 
scaling: none (0), trace (1), mild (2), moderate (3) and severe (4). For the ocular signs, conjunctival hyperaemia 
was assessed using reference photographs and a similar scale as with ocular symptoms. Fluorescein staining of 
the cornea and nasal and temporal conjunctiva was measured according to the Oxford grading scale from 0 to 5 
and FTBUT was evaluated under a slit lamp microscope (seconds). Lid redness was evaluated as none (0), mild 
(1), moderate (2) and severe (3) and tear secretion was measured using Schirmer’s test (mm), from which tear 
proteins were isolated for proteomics analysis. Clinical examinations and sample collections were performed at 
the same time of the day during each visit. No tear samples were collected during the last visit (V6, ~12.5 months 
after baseline).
Tear fluid collection and sample preparation. Patients’ tear fluid samples were collected with Schirmer’s 
strips without anaesthesia (Tear Touch, Madhu Instruments, New Delhi, India). The strips were inserted under 
patients’ lower eyelids and removed after 5 min. Tear amounts (mm) were recorded and strips were then stored at 
−80 °C until proteomic analyses.
For extraction of tear proteins, Schirmer’s strips were first cut into small pieces and solubilized in 50 mM 
ammonium bicarbonate solution containing Protease Inhibitor Cocktail (Thermo Fisher Scientific Inc., Waltham, 
MA, USA) for 3 h. Samples were then centrifuged and total protein concentration of the supernatants was meas-
ured. Up to 50 µg of protein from each sample was dried in a speed vacuum concentrator. Further information of 
the methods, including denaturation, alkylation, reduction and tryptic digestion as well as analysis with Eksigent 
425 NanoLC coupled with high speed TripleTOF 5600+ mass spectrometer (Ab Sciex, Concord, Canada) can be 
found from the Supplementary methods and from our previous publication15.
SWATH library creation and peak integration. SWATH library was created with ProteinPilot soft-
ware version 4.6 (Sciex, Canada). The library was used to analyse MS/MS data and search against the Uniprot 
reviewed library (Swiss-Prot) for protein identification. Some important settings in the Paragon search algorithm 
in ProteinPilot were configured as follows. Sample type: identification, Cys-alkylation: IAA, Digestion: Trypsin, 
Instrument: TripleTOF 5600+, Search effort: thorough ID. False discovery rate (FDR) analysis was performed in 
the ProteinPilot and FDR < 1% was set for protein identification. The data from all the identification runs from 
patients were combined as a batch and used for library creation. PeakView software 2.0 with SWATH was used 
Figure 6. Study outline summary. During the screening/baseline visit (V1), the patients were switched from 
preserved latanoprost (L) to preservative-free tafluprost (T) in unit dose dispensers. Clinical measurement 
together with the tear sample collection were performed at visits V1-V5. At the post-study visit (V6), final 
clinical measures were recorded but tear samples were no longer collected. FTBUT, fluorescein tear break-up 
time.
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to assign the correct peaks to correct peptides in the library. iRT peptides (Biognosys, Switzerland) were used for 
retention time calibration with PeakView. 1–12 peptides per protein and 5 transitions per peptide were selected 
to be used in SWATH quantification. All shared peptides were excluded from analysis. SWATH plug-in FDR 
Analysis was used to select the proper peptides for use in quantification. All proteins with significant or interest-
ing findings in the data analysis were subjected to manual inspection of peptides. This consisted of checking cor-
rect peak selection in the chromatogram (FDR 1%, 99% peptide confidence level), sufficient signal to noise ratio 
inspection (>7) and chromatogram inspection in relation to library chromatogram. All peptides were eliminated 
from results processing if manual inspection requirements were not fulfilled.
Data processing and statistical analysis. Log2-transformation and quantile normalization were applied 
to all quantification results. The majority of the samples had two replicate MS analyses and the variation between 
them was evaluated by intraclass correlation (ICC package in R) and by permutation tests using Spearman’s rank 
correlation coefficients. The replicate MS analyses were then combined by taking geometric means.
For the clinical data, two-tailed paired t-test for continuous and paired 2-group Wilcoxon signed rank test for 
ordinal clinical signs and symptoms were used to evaluate how the clinical signs and symptoms changed during 
visits. For proteomic data, fold changes (log2) between baseline and other visits were analysed using hierarchical 
clustering (Euclidean distance measure and Ward’s method as the criteria) in order to identify clustered groups of 
proteins with association to ocular surface complications. The clusters of interest were identified using Ingenuity 
Pathway Analysis (IPA) and confirmed by identifying well-known biomarkers. The chosen protein clusters were 
used to group patients based on their proteome changes, again using the same hierarchical clustering method. 
Welch’s analysis of variance (ANOVA) was used to establish proteins, which could separate these patient groups 
based on their baseline expression levels alone. Pairwise comparisons were conducted to the statistically signifi-
cant results, which did not suffer from heteroscedasticity according to Levene’s test for homogeneity of variance 
(p-value > 0.05). The linear relationship between proteins and the clinical signs was measured either by mixed 
model regression (lmer function from lme4 package in R38) or cumulative link mixed model (clmm function 
from ordinal package in R39) in order to account for the repeated measures from the same patients. The changes in 
clinical signs and symptoms among patient groups were again analysed conducting paired t-test for continuous 
and paired 2-group Wilcoxon signed rank test for ordinal variables.
Manual peak checking was implemented for the proteins of interest and as a result, some statistically signifi-
cant proteins were omitted from the results due to poor peptide matching. Benjamini & Hochberg correction was 
applied to p-values and only proteins with an adjusted p-value below threshold (alpha = 0.05) were considered 
unless otherwise stated. All statistical analyses for the proteomics data were performed using R software ver-
sion 3.2.3 (R Core Team. Foundation for Statistical Computing, Vienna, Austria) and QIAGEN’s IPA (QIAGEN 
Redwood City, USA).
Data availability. The data generated and analysed during the current study are not publicly available due to 
a pending patent application but are available from the corresponding author on reasonable request.
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